Anticorps Monoclonal Anti - HA - Biotin PRODUIT dans la souris, clone HA - 7, immunoglobulin PURIFIÉE,solution aqueuse tamponnée

Code: b9183-100ug D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Antibody suitable for immunoblotting.

General description

The Monoclonal Anti-HA Biotin Conjugate antibody recognizes the HA tag sequ...


en savoir plus

Votre prix
£538.00 100UG
£645.60 inc. VAT

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Antibody suitable for immunoblotting.

General description

The Monoclonal Anti-HA Biotin Conjugate antibody recognizes the HA tag sequence on the HA tagged fusion proteins when expressed at the N or C terminal to the fusion protein. This antibody is derived from the HA-7 hybridoma, which is produced from the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide corresponding to the amino acid residues 98-106 (YPYDVPDYA) of human Influenza virus hemagglutinin (HA) known as HA-tag, conjugated to KLH. Ascites fluid collected from the HA-7 hybridoma is then conjugated to biotin.

Immunogen

synthetic peptide corresponding to a fragment of human influenza virus hemagglutinin (HA) known as HA-tag, conjugated to KLH

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% bovine serum albumin and 15 mM sodium azide.

Specificity

The antibody recognizes native as well as denatured-reduced forms of HA-tagged proteins and is reactive with N- or C-terminal HA-tagged fusion proteins expressed in E. coli or in mammalian cells.

antibody formpurified from hybridoma cell culture
antibody product typeprimary antibodies
biological sourcemouse
cloneHA-7, monoclonal
concentration~1 mg/mL
conjugatebiotin conjugate
formbuffered aqueous solution
Quality Level200
shipped indry ice
storage temp.−20°C, 2-8°C
technique(s)western blot (chemiluminescent): 0.25-0.50 µg/mL using HA tagged fusion proteins in transiently transfected mammalian cell extracts.
Ce produit répond aux critères suivants: